Pharmafile Logo

OPEN Health Presents First Collection of Research Backed by Scientific Buyout Fund to Foster Research and Development

November 11, 2024 |  

OPEN Health is excited to announce the upcoming presentation of a collection of research supported by its Scientific Buyout Program. This initiative empowers our team members to dedicate time toward innovative projects in HEOR and market access. We’re proud to invest in our team’s growth and scientific excellence.

OPEN Health Presents First Collection of Research Backed by Scientific Buyout Fund to Foster Research and Development

London, Nov 11, 2024 — OPEN Health, a preeminent global provider of scientific communicationsHEOR and market accesspatient engagement, and consulting services, today announced the upcoming presentation of a collection of research supported by its Scientific Buyout Program. The Scientific Buyout Program initiative allows staff members to “buy out” time from their regular duties to engage in important scientific projects, including developing manuscripts, exploring new methodologies, conducting research, and preparing conference presentations.

“Our Scientific Buyout Program reflects our dedication to fostering a culture of scientific excellence and collaboration,” said Professor Ben van Hout, Scientific Founder, OPEN Health HEOR & Market Access. “By providing the opportunity to focus on self-chosen projects, we aim to enhance our contributions to the HEOR and market access fields while encouraging professional development within our team.”

The program runs in three rounds each year, with the first two rounds in 2024 already demonstrating significant participation and promising outcomes. In total, 83 scientists across OPEN Health submitted their project proposals, resulting in 26 projects shortlisted and presented to the Scientific Office. Ultimately, 65% of projects were accepted and funded, highlighting that the time allocation provided through the initiative further drives advanced research.

As a result, OPEN Health is proud to announce that 12 presentations will be made at two international conferences in 2024, including 9 posters at the prestigious ISPOR EU conference in Barcelona. The posters cover the key topics of the conference including the use and acceptability of AI in HTA, patient engagement in HTA, and EU HTA processes, among others, and will feature the “Funded by the Scientific Office” stamp, emphasizing the support behind these projects.

Elisabeth Fenwick, Chief Scientific Officer at OPEN Health, added, “This program not only empowers our scientists but also fosters a collaborative environment where new ideas can thrive. We believe that investing in our scientific talent is crucial for driving progress in healthcare.”

For more information about the Scientific Buyout Program and OPEN Health’s commitment to scientific advancement, please visit https://www.openhealthgroup.com/what-we-do/heor-market-access/

 

About OPEN Health: OPEN Health unites world-class scientific, strategic, and creative expertise to solve complex challenges for global biopharma. We are a flexible, global organization, creating high-performing strategic partnerships with our clients. We embrace our different perspectives and strengths to deliver innovative solutions that have a positive impact on commercial and patient outcomes. OPEN Health unlocks possibilities across consulting, HEOR and market access, scientific communications, and patient engagement. To learn more, visit www.openhealthgroup.com.

Contact:

Candice Subero

OPEN Health

candicesubero@openhealthgroup.com

This content was provided by OPEN Health

Company Details

 Latest Content from  OPEN Health 

OPEN Health’s Learning & Development team have won a Bronze Award at the PM Society Digital Awards 2020

We are delighted to have won a Bronze Award at the PM Society Digital Awards 2020 for  Excellence in Innovation: Immunology Training Summit.READ MORE ABOUT OUR WINNING PROJECT WITH WITH JANSSEN BELOW:The Immunology...

OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020

We are delighted to have won a Bronze Award at the PM Society Digital Awards 2020 for Effectiveness: Market Access.READ MORE ABOUT OUR WINNING PROJECT “VAGUS NERVE STIMULATION - ADDRESSING INEQUALITY...

Meet OPEN Health and Pharmerit Experts at the World Pharma Pricing Market Access and Evidence Congress 2020

Join OPEN Health and Pharmerit – an OPEN Health Company at the World Pharma Pricing Market Access and Evidence Congress from 23 – 25 September 2020, as we present:ROUNDTABLE: Wednesday, September 23,...

Reflections of a Fireside Chat from the World Orphan Drug Congress 2020

Hear from Trish Shepherd COO, Patient & Brand Communications, OPEN Health

OPEN Health has been awarded a Bronze Medal by EcoVadis

We are delighted to announce that OPEN Health has been awarded a Bronze Medal by EcoVadis for its very first Corporate Social Responsibility assessment in recognition of its commitment to Corporate Social...

Digital Therapeutics Landscape in Europe

OPEN Health introduce an overview of regulatory and HTA developments for digital therapeutics in Europe focusing on Germany and the UK

OPEN Health’s virtual reflections on the World Orphan Drug Congress US

Another congress attended in this virtual world with learnings gathered and connections made across the rare disease community. It was great to be joined by many colleagues from all our...

A day in the life of the Global Head of Publications

We asked Mina Patel to give us an insight into her role as Global Head of Publications at OPEN Health

Striving to become more patient-centric?

Explore more with OPEN Health

Meet OPEN Health and Pharmerit Experts at the World Orphan Drug Virtual USA Congress

Join OPEN Health and Pharmerit – an OPEN Health Company at the World Orphan Drug Virtual Congress from August 24-27, 2020, as we present:Advanced Therapies Commercial: Tuesday, August 25Succeeding with Star Wars...